12-month intravascular ultrasound observations from BiOSS® first-in-man studies

Autor: Jacek Bil, Ricardo Costa, Dobrin Vassiliev, Katarzyna Gil, Robert J. Gil
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Male
Dedicated bifurcation stent
Time Factors
medicine.medical_treatment
Coronary Artery Disease
030204 cardiovascular system & hematology
BiOSS Expert®
Coronary Angiography
Main branch
0302 clinical medicine
Intravascular ultrasound
BiOSS LIM®
030212 general & internal medicine
Registries
Angioplasty
Balloon
Coronary
Non-ST Elevated Myocardial Infarction
medicine.diagnostic_test
Drug-Eluting Stents
Middle Aged
Expert group
Coronary Vessels
Treatment Outcome
Radiology Nuclear Medicine and imaging
cardiovascular system
Cardiology
Female
Cardiology and Cardiovascular Medicine
Neointima
medicine.medical_specialty
Paclitaxel
Prosthesis Design
Paclitaxel-eluting stent
03 medical and health sciences
Main vessel
Predictive Value of Tests
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
cardiovascular diseases
Ultrasonography
Interventional
Aged
Cell Proliferation
IVUS
Sirolimus
Original Paper
Sirolimus-eluting stent
QCA
business.industry
Quantitative angiography
Late Lumen Loss
Stent
Cardiovascular Agents
business
Zdroj: The International Journal of Cardiovascular Imaging
ISSN: 1875-8312
1569-5794
Popis: The aim of this study was to analyze the difference in neointima pattern assessed by intravascular ultrasound (IVUS) between two dedicated bifurcation stents, BiOSS® Expert and BiOSS® LIM at 12-month follow-up. This manuscript reports IVUS findings obtained from the analysis of patients enrolled into first-in-man registries initially assessing the BiOSS Expert® (paclitaxel) and BiOSS LIM® (sirolimus) stents. Quantitative angiographic analysis was performed pre, post-stenting, and at follow-up. IVUS examination was performed at 12 months. There were analyzed 34 cases (BiOSS Expert® 11 patients, BiOSS LIM® 23 patients). Procedural characteristics in the two groups were similar, except for rates of main vessel predilatation and FKB/POT, which were higher in BiOSS® LIM group, 54.5 % vs 73.9 % (P
Databáze: OpenAIRE
Externí odkaz: